CN106852919A - A kind of pharmaceutical composition for treating asthma - Google Patents
A kind of pharmaceutical composition for treating asthma Download PDFInfo
- Publication number
- CN106852919A CN106852919A CN201611058438.0A CN201611058438A CN106852919A CN 106852919 A CN106852919 A CN 106852919A CN 201611058438 A CN201611058438 A CN 201611058438A CN 106852919 A CN106852919 A CN 106852919A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- treating asthma
- dioxasampsone
- asthma
- phytolaccatoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating asthma, active ingredient includes Dioxasampsone B, also including phytolaccatoxin fourth.The present invention has good effect by Dioxasampsone B and phytolaccatoxin fourth use in conjunction for treatment and prevention of asthma.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for treating asthma, belong to pharmaceutical technology field.
Background technology
With industrial expansion, polluted because of living environment in recent years, dietetic life changes, diversified mistake
Quick property disease increases, and in the middle of these anaphylactias, especially the incidence of disease of asthma is greatly increased.Asthma is with chronic
The tuberculosis that airway inflammation and airway allergic are characterized, asthma is because Air Pollutants, dust storm, anaphylactogen etc. cause.It is reported that,
The asthma prevalence of children becomes higher than adult, and the change with eating habit and European-styled, asthma prevalence in growth
Gesture.
The medicine for being presently used for treating asthma has anabolic agent, bronchodilator or biocide etc..Steroids system
Agent and biocide treat asthma by suppressing immune response and inflammatory reaction, and bronchodilator is when appearance expiratory dyspnea etc.
During clinical symptoms, asthma is treated by offsetting these symptoms.But these medicines have including suppressing immune, suppressing marrow generation
Deng side effect side effect is there is also in the interior biocide resistance to the action of a drug, and during long-term use, therefore it is used as treating
The therapeutic agent of asthma is very limited.Therefore, all the time, it is relevant that above-mentioned side effect, small toxicity, therapeutic effect can be overcome outstanding
Natural goods or the research and development of new compound constantly carry out.One kind that Dioxasampsones B Samson St Johswort is separated is complete
The compound of new skeleton, is published in Dioxasampsones A and B, Two Polycyclic Polyprenylated
Acylphloroglucinols with Unusual Epoxy-Ring-Fused Skeleton from Hypericum
Sampsonii Org.Lett., 2014,16 (24), 6346-6349, it is found by the applicant that Dioxasampsone B and phytolaccatoxin
Fourth has good effect in terms of asthma is treated.
The content of the invention
For the problem that above-mentioned prior art is present, the present invention provides a kind of pharmaceutical composition for treating asthma.
To achieve these goals, the technical solution adopted by the present invention is：A kind of pharmaceutical composition for treating asthma, effectively
Composition includes Dioxasampsone B, and structural formula is as follows：
Active ingredient includes also including phytolaccatoxin fourth.
Calculated according to weight, Dioxasampsone B and phytolaccatoxin fourth ratio are 15:1-20:1.
The preferred solid orally ingestible of the pharmaceutical composition；
Further, described oral formulations are tablet, capsule, granule, dry suspensoid agent or dripping pill.
It should be noted that available auxiliary material in pharmacy of the present invention, refers to be included in agent in addition to the active ingredient (s
Inert matter in type, includes but are not limited to filler (diluent), lubricant (glidant or antitack agent), dispersion
Agent, wetting agent, adhesive, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc..Adhesive includes syrup, Arab
Glue, gelatin, sorbierite, tragacanth, cellulose and its derivates (such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose
Or HPMC etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.；Filler comprising lactose, Icing Sugar,
Dextrin, starch and its derivative, cellulose and its derivates, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, sedimentation carbon
Sour calcium etc.), sorbierite or glycine etc.；Lubricant includes superfine silica gel powder, magnesium stearate, talcum powder, aluminium hydroxide, boric acid, hydrogen
Change vegetable oil, polyethylene glycol etc.；Disintegrant includes starch and its derivative (such as sodium carboxymethyl starch, Explotab, pre- glue
Change starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.；Wetting agent bag
Containing lauryl sodium sulfate, water or alcohol etc.；Antioxidant packages contain sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid
Deng.
A kind of pharmaceutical composition for treating asthma that the present invention is provided, by Dioxasampsone B and phytolaccatoxin fourth
Use in conjunction, test result indicate that, Dioxasampsone B and phytolaccatoxin fourth are 6:1-9:In 1 ratio, treat and prevent
Asthma aspect has extraordinary effect.
Specific embodiment
Described above is only the general introduction of technical solution of the present invention, in order to better understand technological means of the invention,
And can be practiced according to the content of specification and ordinary skill in the art means, animal experiment of the invention example is done below
It is described in further detail.
Chinese:Phytolaccatoxin fourth CAS:89808-50-4, is commercial goods.
The preparation method of compound Dioxasampsone B involved in the present invention is referring to document：(Dioxasampsones A
and B,Two Polycyclic Polyprenylated Acylphloroglucinols with Unusual Epoxy-
Ring-Fused Skeleton from Hypericum sampsonii Org.Lett.,2014,16(24),6346–
6349,.)
The test of pesticide effectiveness：
Modeling：210 male mices, 100~140g of weight, 22~25 DEG C of experimental animal feeding temperature, relative humidity
45%~75%.10 groups are randomly divided into, every group 10, there is one group of blank group not inject any medicine.In addition to normal group, every small
Mouse iP sensitization liquid (including 100ugOVA, 3mg aluminium hydroxides) 0.2ml, dorsal sc injection equivalent sensitization liquid, repetition in the 8th day is caused
Quick 1 time since mouse to be put into nose exposure/systemic exposure Inhalation system 15d.It is atomized with the speed of 2ml/min
The white egg of 1% egg white (exciting liquid), each 20min, 2d 1 time, continuous 28d starts ip in mice administration, correspondence group during experiment 15d
Correspondence is to medicament.Normal group mouse injection grape 20ml/kg.Continuous 28d once a day.Since after mouse administration 8h the 29th day
Ip thyroid glands (0.5% xanthans suspending) 120mg/kg, once a day continuous 14d.
Test method；Pulmonary function detection, experiment is carried out when to 48d, and the lung work(of mouse is determined using PFT check system
Can respiratory rate F, tidal volume TV.
The respiratory rate of the mouse of table one, the detection of tidal volume.(x ± s, n=10, p<0.05).
A is Dioxasampsone B, and B is phytolaccatoxin fourth
| Active ingredient | Dosage (g/kg) | F/pbm | TV/ul |
| A:B(20:1) | 5 | 170.4±3.2 | 85.3±6.2 |
| A:B(20:1) | 10 | 163.5±6.3 | 89.4±1.7 |
| A:B(15:1) | 5 | 169.6±5.5 | 92.7±5.5 |
| A:B(15:1) | 10 | 166.1±3.7 | 87.1±3.2 |
| A:B(11:1) | 5 | 170.4±1.3 | 98.5±6.5 |
| A:B(11:1) | 10 | 165.7±5.4 | 101.8±5.7 |
| A:B(9:1) | 5 | 129.2±4.1 | 124.7±2.2 |
| A:B(9:1) | 10 | 121.3±3.7 | 130.4±5.5 |
| A:B(6:1) | 5 | 147.4±7.2 | 115.3±3.6 |
| A:B(6:1) | 10 | 135.8±8.4 | 124.3±6.5 |
| A:B(2:1) | 5 | 172.1±1.2 | 88.4±2.4 |
| A:B(2:1) | 10 | 161.6±3.3 | 93.5±1.5 |
| A:B(1:1) | 5 | 168.2±1.5 | 92.7±6.5 |
| A:B(1:1) | 10 | 163.5±5.4 | 99.1±5.7 |
| A:B(1:5) | 5 | 171.3±3.3 | 91.4±3.5 |
| A:B(1:5) | 10 | 169.1±4.4 | 96.5±6.7 |
| A | 5 | 189.4±6.1 | 81.6±1.5 |
| A | 10 | 183.7±4.3 | 87.2±6.4 |
| B | 5 | 176.6±6.4 | 97.7±3.6 |
| B | 10 | 171.3±4.7 | 89.4±5.6 |
| Normal group | 113.2±3.5 | 134.3±2.8 |
Injection certain proportion (6 may indicate that according to measurement result:1-9:1) Dioxasampsone B and phytolaccatoxin fourth
Mice Body respiratory rate be below other groups, and its respiratory rate is close to normal mouse, best to treating asthma, it is seen that
Dioxasampsone B and phytolaccatoxin fourth are (6:1-9:1) there is significant effect for preventing and treating asthma during mixture
Really.
Claims (5)
1. a kind of pharmaceutical composition for treating asthma, it is characterised in that active ingredient includes Dioxasampsone B, structural formula
It is as follows：
2. a kind of pharmaceutical composition for treating asthma according to claim 1, it is characterised in that active ingredient also includes business
Land saponin fourth.
3. a kind of pharmaceutical composition for treating asthma according to claim 2, it is characterised in that calculated according to weight,
Dioxasampsone B and phytolaccatoxin fourth ratio are 1:1-20:1.
4. a kind of pharmaceutical composition for treating asthma according to claim 2, it is characterised in that calculated according to weight,
Dioxasampsone B and phytolaccatoxin fourth ratio are 3:1-15:1.
5. a kind of pharmaceutical composition for treating asthma according to claim any one of 1-3, it is characterised in that：Described medicine
Composition is oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611058438.0A CN106852919A (en) | 2016-11-27 | 2016-11-27 | A kind of pharmaceutical composition for treating asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611058438.0A CN106852919A (en) | 2016-11-27 | 2016-11-27 | A kind of pharmaceutical composition for treating asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106852919A true CN106852919A (en) | 2017-06-16 |
Family
ID=59125650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611058438.0A Withdrawn CN106852919A (en) | 2016-11-27 | 2016-11-27 | A kind of pharmaceutical composition for treating asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106852919A (en) |
-
2016
- 2016-11-27 CN CN201611058438.0A patent/CN106852919A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107175070A (en) | It is a kind of efficient except formaldehyde de-tastes air cleaning adsorbent and preparation method | |
| RU2006112589A (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING PREMATURE EJACULATION USING PULMONARY INHALATION | |
| CN106667975A (en) | Preparation method of ipratropium bromide solution for inhalation | |
| US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| JP2023532972A (en) | glucocorticoid sparing agent | |
| CN104622854A (en) | Tablet containing ambroxol hydrochloride and salbutamol sulfate | |
| CN106852919A (en) | A kind of pharmaceutical composition for treating asthma | |
| CN109260180A (en) | A kind of moxifloxacin hydrochloride Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN109771417A (en) | A kind of pharmaceutical composition for treating asthma | |
| CN104224819B (en) | A kind of naringin and levo-cetirizine hydrochloride pharmaceutical composition and preparation thereof | |
| CN101023953B (en) | Composition for treating bronchia asthma | |
| WO2015135372A1 (en) | Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease | |
| CN102166213A (en) | Composition using levalbuterol and ipratropium bromide as active ingredients | |
| CN102793696B (en) | Application of butylphthalide in preparation of medicament for treating bronchial asthma | |
| CN107496558B (en) | Composition for treating cough and application thereof | |
| CN102266344A (en) | Pharmaceutical composition used for treating respiration disorders | |
| CN114099480A (en) | Atomizing inhalation type polydatin solution and preparation method thereof | |
| WO2016041438A1 (en) | Naringin and fexofenadine hydrochloride pharmaceutical composition and preparation thereof | |
| CN101347618A (en) | Medicament composition for treating respiratory disease | |
| CN101897719A (en) | Medical composite used for treating smoke inhalation lung injury | |
| CN102000089A (en) | Compound preparation with ciclesonide and Arformoterol as active constituents | |
| CN109498625B (en) | Pharmaceutical composition for treating chronic obstructive pulmonary disease and preparation method thereof | |
| CN110613702A (en) | Clenbuterol solution preparation for aerosol inhalation and preparation method thereof | |
| CN107595868B (en) | Application of the desgalactotigonin in preparation treatment bronchitis drug | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170616 |